Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a report issued on Monday. They currently have a $30.00 price target on the biotechnology company’s stock, down from their prior price target of $31.00. Stifel Nicolaus’ price objective points to a potential upside of 119.94% from the stock’s previous close.
Several other research firms also recently weighed in on CNCE. Aegis reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Concert Pharmaceuticals in a report on Wednesday, April 5th. ValuEngine raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Finally, Zacks Investment Research downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Monday, May 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Concert Pharmaceuticals currently has an average rating of “Buy” and an average price target of $26.20.
Shares of Concert Pharmaceuticals (NASDAQ:CNCE) traded down 3.54% during mid-day trading on Monday, hitting $13.64. 132,876 shares of the company traded hands. The firm’s market cap is $307.75 million. Concert Pharmaceuticals has a 52-week low of $7.11 and a 52-week high of $19.11. The firm has a 50-day moving average price of $13.85 and a 200 day moving average price of $12.95.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.06. The company had revenue of $0.02 million during the quarter. Concert Pharmaceuticals had a negative return on equity of 55.30% and a negative net margin of 36,357.25%. Equities research analysts anticipate that Concert Pharmaceuticals will post ($2.70) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.wkrb13.com/markets/2286498/concert-pharmaceuticals-inc-nasdaqcnce-given-buy-rating-at-stifel-nicolaus.html.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Concert Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 681,712 shares of the biotechnology company’s stock worth $11,630,000 after buying an additional 38,892 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Concert Pharmaceuticals by 34.8% in the fourth quarter. Renaissance Technologies LLC now owns 435,800 shares of the biotechnology company’s stock worth $4,484,000 after buying an additional 112,396 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of Concert Pharmaceuticals during the first quarter worth $7,353,000. State Street Corp increased its stake in shares of Concert Pharmaceuticals by 3.8% in the fourth quarter. State Street Corp now owns 349,505 shares of the biotechnology company’s stock worth $3,594,000 after buying an additional 12,690 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in shares of Concert Pharmaceuticals by 26.2% in the first quarter. Prudential Financial Inc. now owns 253,130 shares of the biotechnology company’s stock worth $4,319,000 after buying an additional 52,500 shares during the last quarter. 62.67% of the stock is owned by institutional investors and hedge funds.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286498/concert-pharmaceuticals-inc-nasdaqcnce-given-buy-rating-at-stifel-nicolaus.html
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.